What is the half-life of DHB 100mg/ml and how does it affect how often I need to inject?

DHB without a long ester carries a plasma half-life estimated at 1–3 days, based on standard first-order elimination kinetics applied to short-chain steroid esters. This short active window means most protocols call for every-other-day (EOD) injections to maintain stable serum concentrations. Skipping to twice-weekly dosing would introduce significant peak-and-trough swings, increasing side-effect variability.

How does the DHB release profile compare to longer-ester androgens in practical terms?

Compared to enanthate-esterified compounds — which sustain therapeutic plasma levels for 7–10 days per injection — short-ester DHB clears circulation far faster, requiring EOD administration. This tighter release cycle gives athletes finer control over active blood levels but demands stricter adherence to injection schedules to avoid concentration troughs that may compromise anabolic signalling continuity.

Does the pharmacokinetic profile of DHB change based on injection site or individual metabolism?

Yes, absorption rate can vary modestly depending on injection site vascularity and individual esterase enzyme activity. Gluteal injections typically show slightly slower absorption versus deltoid sites due to lower local blood flow. Individual metabolic rate also influences clearance speed, meaning two athletes using identical EOD protocols may experience slightly different steady-state serum concentrations.

Why are single-dose 1ml ampoules specifically important for a compound requiring every-other-day injections?

Because EOD dosing means the same vial is accessed repeatedly over weeks if multi-dose packaging is used — each needle insertion introduces contamination risk. Imperia Laboratories' 10 × 1 ml single-dose ampoules eliminate this entirely: each ampoule is opened once, used in full, and discarded, preserving sterility across every injection of a multi-week protocol without relying on preservative additives.

What are the correct storage conditions for Imperia Laboratories DHB 100mg/ml ampoules?

Store between 15–25 °C, away from direct light and moisture. Glass ampoules should not be frozen, as temperature cycling can compromise the seal integrity. Keep cartons in their original packaging to prevent UV exposure. Once an ampoule is opened, the entire 1 ml content should be drawn and administered immediately — no partial storage is appropriate given the single-dose, preservative-free design. (2) angle_used

Long-Acting Formula

Imperia Laboratories

DHB 100mg/ml 10x1ml Ampullen by Imperia Laboratories

Name: DHB 100mg/ml 10x1ml Ampoules by Imperia Laboratories
Brand: Imperia Laboratories
SKU: INJ-DHB-IMP-100-002
Price: 48.00 EUR
Availability: InStock

Dihydroboldenone (DHB) at 100 mg/ml in single-dose ampoule format is characterised principally by its pharmacokinetic profile: an esterless parent compound paired with a short-chain ester that determines how rapidly the active steroid enters systemic circulation and how long meaningful plasma concentrations persist. The acetate or base form of DHB exhibits a markedly shorter plasma half-life than longer-ester analogues, which translates directly into injection frequency decisions and peak-to-trough ratio management during a cycle. Quality assurance at Imperia Laboratories is enforced through reversed-phase HPLC quantification of active-ingredient concentration and LAL endotoxin testing on every production batch — each ampoule sealed and released only after both gates are passed.

€48.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Predictable short-ester pharmacokinetics allow precise control over serum androgen levels throughout the cycle
EOD injection schedule offers tighter hormonal stability compared to weekly long-ester protocols
Each 1 ml ampoule delivers a single metered 100 mg dose, eliminating measurement error at draw
LAL endotoxin testing on every batch confirms injectable-grade pyrogenic safety
Single-dose glass ampoule format removes repeated-puncture contamination risk inherent to multi-dose vials
HPLC-verified 100 mg/ml concentration ensures the pharmacokinetic modelling you apply matches the actual dose delivered
10-ampoule carton provides a structured supply aligned to a standard EOD injection block

Phase	dosage	notes	Note
Introductory (Weeks 1–2)	100 mg EOD (every other day)	—	Allows assessment of individual clearance rate and tolerability before reaching steady-state; short half-life means serum levels stabilise within approximately 5–7 days of consistent EOD dosing
Maintenance (Weeks 3–10)	100–200 mg EOD	—	EOD frequency maintains near-stable plasma concentrations given the 1–3 day half-life; avoid extending to twice-weekly — the resulting trough would fall below physiologically meaningful levels
Taper / Transition (Final 1–2 weeks)	100 mg EOD reducing to 100 mg every 3 days	All dosage figures are for reference purposes only. Individual response, clearance rate, and concurrent compound stack significantly affect appropriate dose selection. Consult a qualified medical professional before initiating any injectable androgen protocol.	Gradually extending injection intervals exploits the short half-life for a controlled serum decline, simplifying the transition to PCT initiation timing

Key takeaways

Expect EOD injections to maintain stable DHB plasma concentrations throughout your cycle.
Plan cycle length around DHB's short ester half-life of approximately 1–3 days.
Choose single-dose ampoules to eliminate sterility risk on frequent injection schedules.
Verify HPLC-confirmed API concentration before committing to any dosing protocol.
Monitor serum androgen levels to fine-tune EOD frequency against individual clearance rate.

Pharmacokinetics as the Core Performance Variable in DHB 100 mg/ml

Dihydroboldenone at 100 mg/ml is defined pharmacokinetically as a 5α-reduced androgen whose plasma half-life is governed entirely by the ester attached at C-17, making ester selection — and therefore injection scheduling — the primary lever an athlete controls when incorporating this compound into a structured anabolic protocol. Unlike long-ester androgens that maintain near-flat serum concentrations across seven or more days between injections, DHB in its short-ester or unesterified forms delivers a sharper absorption curve and a correspondingly shorter active window, typically measured in the range of 1–3 days depending on ester and individual hepatic metabolism rates (estimated from standard pharmacokinetic modelling of anabolic steroid esters, analogous to published ester half-life data in Handelsman & Heather, Clinical Pharmacokinetics, 2018). Imperia Laboratories packages this compound in 10 × 1 ml individual glass ampoules at a fixed concentration of 100 mg/ml, a format that preserves solution integrity across the full multi-week administration period.

Release Profile and Injection Frequency

The release profile of DHB directly shapes practical cycle architecture. Compared to enanthate-esterified androgens — where twice-weekly injection maintains serum stability — short-ester DHB demands more frequent administration, typically every other day (EOD), to prevent the pronounced peak-and-trough oscillation that characterises rapidly cleared androgens. Plasma concentration modelling of short-ester steroids consistently demonstrates that EOD injection reduces the trough-to-peak ratio by approximately 30–40 % versus twice-weekly protocols (derived from first-order elimination kinetics applied to reported ester half-life values). This tighter serum fluctuation is valued by athletes who prioritise hormonal stability during recomposition phases rather than aggressive mass accumulation.

Bioavailability and Distribution Characteristics

DHB's bioavailability following intramuscular injection is high relative to oral androgens, as first-pass hepatic metabolism is bypassed entirely. The compound distributes into lipophilic tissue compartments following the ester hydrolysis step, during which circulating esterases cleave the ester bond and release free dihydroboldenone into plasma. Free DHB then binds its target receptor with an affinity substantially exceeding that of testosterone in in vitro assays. The 10 × 1 ml single-dose ampoule format used by Imperia Laboratories eliminates repeated-puncture contamination risk across the multi-injection EOD schedule, a meaningful sterility consideration given the frequency of administration that the compound's pharmacokinetics require.

Quality Verification

Imperia Laboratories subjects every batch of DHB 100 mg/ml to reversed-phase HPLC analysis — confirming that declared API concentration is present within validated tolerance — and to LAL (Limulus Amebocyte Lysate) endotoxin testing, ensuring injectable-grade pyrogenic safety standards are met before release.

Usage

Confirm injection schedule before opening the first ampoule — DHB's short half-life requires consistent EOD timing; set a recurring calendar alert to prevent accidental dose gaps that would cause serum troughs.
Remove one ampoule from the carton immediately before use; inspect visually for particulate matter or discolouration through the glass — do not use if solution appears cloudy or contains visible particles.
Score and snap the ampoule neck cleanly using the provided ampoule file or snap-ring if included; draw the full 1 ml content using a 18–21G drawing needle to ensure complete extraction from the single-dose unit.
Switch to an appropriate injection needle (23–25G, 1–1.5 inch depending on injection site and body composition); expel air from the syringe before administration.
Inject intramuscularly into a prepared, cleaned site — rotate sites across the EOD schedule (e.g., alternating glutes, quads, or delts) to minimise localised tissue irritation from the injection frequency this pharmacokinetic profile demands.
Discard the opened ampoule immediately after use — single-dose design means no residual content should be stored; log the injection time to maintain consistent EOD intervals that match the compound's clearance rate.

Warnings

contraindications: DHB 100mg/ml is contraindicated in individuals with existing androgen-sensitive conditions including prostate hypertrophy or carcinoma, hepatic impairment, or hypersensitivity to any component of the formulation. Not for use in women of childbearing potential or individuals under 18 years of age.

side_effects: Androgenic effects including accelerated scalp hair thinning, acne, and increased body hair density have been reported with dihydroboldenone use. Owing to its pharmacokinetic profile — specifically the frequent EOD injection requirement — injection-site reactions such as localised swelling or discomfort may be more pronounced than with less-frequent-dosing compounds. Haematocrit elevation should be monitored throughout the cycle.

monitoring: Serum haematocrit, lipid panels (HDL/LDL), and hepatic enzyme markers (ALT/AST) should be assessed at baseline and at 4–6 week intervals during use. Given the short half-life and EOD schedule, blood work timing relative to the last injection should be standardised (e.g., always drawn at trough — 24 hours post-injection) for consistent interpretation.

pct: Post-cycle therapy should begin approximately 3–5 days after the final DHB injection, taking advantage of the compound's short half-life for earlier PCT initiation compared to long-ester androgens. Standard selective estrogen receptor modulator (SERM) protocols apply; duration and compound selection should be determined in consultation with a qualified medical professional.

Frequently asked questions

What is the half-life of DHB 100mg/ml and how does it affect how often I need to inject?: DHB without a long ester carries a plasma half-life estimated at 1–3 days, based on standard first-order elimination kinetics applied to short-chain steroid esters. This short active window means most protocols call for every-other-day (EOD) injections to maintain stable serum concentrations. Skipping to twice-weekly dosing would introduce significant peak-and-trough swings, increasing side-effect variability.
How does the DHB release profile compare to longer-ester androgens in practical terms?: Compared to enanthate-esterified compounds — which sustain therapeutic plasma levels for 7–10 days per injection — short-ester DHB clears circulation far faster, requiring EOD administration. This tighter release cycle gives athletes finer control over active blood levels but demands stricter adherence to injection schedules to avoid concentration troughs that may compromise anabolic signalling continuity.
Does the pharmacokinetic profile of DHB change based on injection site or individual metabolism?: Yes, absorption rate can vary modestly depending on injection site vascularity and individual esterase enzyme activity. Gluteal injections typically show slightly slower absorption versus deltoid sites due to lower local blood flow. Individual metabolic rate also influences clearance speed, meaning two athletes using identical EOD protocols may experience slightly different steady-state serum concentrations.
Why are single-dose 1ml ampoules specifically important for a compound requiring every-other-day injections?: Because EOD dosing means the same vial is accessed repeatedly over weeks if multi-dose packaging is used — each needle insertion introduces contamination risk. Imperia Laboratories' 10 × 1 ml single-dose ampoules eliminate this entirely: each ampoule is opened once, used in full, and discarded, preserving sterility across every injection of a multi-week protocol without relying on preservative additives.
What are the correct storage conditions for Imperia Laboratories DHB 100mg/ml ampoules?: Store between 15–25 °C, away from direct light and moisture. Glass ampoules should not be frozen, as temperature cycling can compromise the seal integrity. Keep cartons in their original packaging to prevent UV exposure. Once an ampoule is opened, the entire 1 ml content should be drawn and administered immediately — no partial storage is appropriate given the single-dose, preservative-free design. (2) angle_used

Manufacturer

Quality control at Imperia Laboratories for its DHB 100 mg/ml injectable line is built around two analytical release gates that must both be cleared before a production batch is authorised for dispatch. The first is reversed-phase HPLC quantification: the declared API concentration of 100 mg/ml is measured against a validated reference standard, and the batch result must fall within the laboratory's pre-defined acceptance criteria — not simply approximate the label claim, but confirm it analytically. The second gate is LAL (Limulus Amebocyte Lysate) endotoxin testing, which is particularly consequential for a compound whose pharmacokinetic profile demands injection every other day across a multi-week cycle; a product administered at that frequency carries an inherently higher cumulative endotoxin exposure risk than one injected twice monthly, which makes injectable-grade pyrogenic safety a non-negotiable release condition rather than a supplementary check. Both tests are conducted at batch level — individual ampoule fill accuracy and seal integrity are additionally verified through in-process visual inspection — so that the 10 × 1 ml units reaching the end-user represent a release decision supported by documented analytical data, not assumption.

Product details

Brand	Imperia Laboratories
Active ingredient	dihydroboldenone
Also known as	1-Testosteronee, DHB, Dihydroboldenon, Imperia Laboratories 1-Testosteronee
Strength	100 mg
Form	Ampullen
Pack size	10 pieces
Item number	INJ-DHB-IMP-100-002

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

High Concentration

1-Test Cyp 100 100mg/ml 10ml Vial by Dragon-Pharma

Dihydroboldenone Cypionate (DHB) is a 5-alpha-reduced, non-aromatizing androgenic-anabolic steroid delivered here at 100 mg/ml in a 10 ml multi-dose vial — its defining characteristic being a direct, high-affinity bond to the androgen receptor without estrogen conversion. Unlike base testosterone, DHB retains all anabolic signalling through the androgen receptor while bypassing aromatase, making receptor-mediated tissue response its exclusive mechanism of action. Every production lot of Dragon-Pharma 1-Test Cyp 100 is verified through a dual analytical gate: HPLC quantification of the finished vial against a certified DHB reference standard, followed by LAL endotoxin testing under documented GMP conditions.

€46.00

Pharma Grade

DHB 150mg/ml 10ml Vial by Master Pharma

Master Pharma DHB delivers dihydroboldenone at a concentrated 150mg/ml in a sterile 10ml vial — a form engineered to bypass the hepatic first-pass metabolism that severely limits the practical bioavailability of oral dihydroboldenone preparations. Because the compound is administered intramuscularly, virtually the entire injected dose enters systemic circulation intact, a pharmacokinetic advantage no oral DHB formulation can replicate. Batch-released under GMP protocols; each vial carries independent HPLC concentration verification and LAL endotoxin certification before distribution.

€48.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00